ADiTx Therapeutics, Inc. (NASDAQ:ADTX) saw a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 2,070,000 shares, an increase of 354.0% from the December 15th total of 455,900 shares. Based on an average trading volume of 3,080,000 shares, the short-interest ratio is currently 0.7 days.
Shares of ADiTx Therapeutics stock opened at $0.46 on Friday. ADiTx Therapeutics has a 52-week low of $0.43 and a 52-week high of $6.73. The company has a 50-day simple moving average of $0.87 and a two-hundred day simple moving average of $1.65.
Separately, Zacks Investment Research cut shares of ADiTx Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, December 10th.
About ADiTx Therapeutics
ADiTx Therapeutics, Inc, a biotech company, develops technologies focuses on improving the health of the immune system through immune reprogramming and monitoring. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues.
Read More: Special Dividends
Receive News & Ratings for ADiTx Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADiTx Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.